Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study

Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study

For early-stage hormone receptor (HR)-positive and HER2-negative breast cancer, tools to estimate treatment benefit include free and publicly available algorithms (e.g., PREDICT 2.1) and expensive molecular assays (e.g., Oncotype DX). There remains a need to identify patients who de-rive the most be...

Full description

Bibliographic Details
Main Authors: Arif Ali Awan, Deanna Saunders, Gregory Pond, Caroline Hamm, Nadia Califaretti, Mihaela Mates, Vikaash Kumar, Mohammed F. K. Ibrahim, Ana-Alicia Beltran-Bless, Lisa Vandermeer, John Hilton, Mark Clemons
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Current Oncology
Subjects:
PREDICT 2.1
Oncotype DX
early-stage HR+ breast cancer
real-world evidence
Online Access:https://www.mdpi.com/1718-7729/31/3/96

Internet

https://www.mdpi.com/1718-7729/31/3/96

Similar Items